Reference
·Supporting source
NHSO Priority CDx Panels Added to Oncology Bundles — FY2026-2027
4-8 priority panels (HER2, EGFR, BRCA, KRAS, ALK, PD-L1)
The National Health Security Office (NHSO) FY2026-2027 National List of Essential Medicines plan prioritises four to eight companion diagnostics panels for inclusion inside oncology bundles under Universal Coverage. Anchor panels are HER2 (breast, gastric), EGFR (lung), BRCA (breast, ovarian), KRAS (colorectal), ALK (lung), and PD-L1 (multiple indications). Reimbursement rates land in the THB 8,000-15,000 range per CDx test depending on panel breadth, materially below private-pay Thai ASPs of THB 18,000-32,000. NHSO bundle inclusion is the single largest demand catalyst behind the THB 12-19B 2027 market projection; independent reference labs and pharma-paired CDx programmes are positioned to capture the scaling NHSO volume.
Figure in context
The National Health Security Office (NHSO) FY2026-2027 National List of Essential Medicines plan prioritises four to eight companion diagnostics panels for inclusion inside oncology bundles under Universal Coverage. Anchor panels are HER2 (breast, gastric), EGFR (lung), BRCA (breast, ovarian), KRAS (colorectal), ALK (lung), and PD-L1 (multiple indications). Reimbursement rates land in the THB 8,000-15,000 range per CDx test depending on panel breadth, materially below private-pay Thai ASPs of THB 18,000-32,000. NHSO bundle inclusion is the single largest demand catalyst behind the THB 12-19B 2027 market projection; independent reference labs and pharma-paired CDx programmes are positioned to capture the scaling NHSO volume.
The National Health Security Office (NHSO) FY2026-2027 National List of Essential Medicines plan prioritises four to eight companion diagnostics panels for inclusion inside oncology bundles under Universal Coverage. Anchor panels are HER2 (breast, gastric), EGFR (lung), BRCA (breast, ovarian), KRAS (colorectal), ALK (lung), and PD-L1 (multiple indications). Reimbursement rates land in the THB 8,000-15,000 range per CDx test depending on panel breadth, materially below private-pay Thai ASPs of THB 18,000-32,000. NHSO bundle inclusion is the single largest demand catalyst behind the THB 12-19B 2027 market projection; independent reference labs and pharma-paired CDx programmes are positioned to capture the scaling NHSO volume.
Time scope
FY2026-2027 bundle inclusion phase
Source basis
Supporting source
Interpretation notes
What this tells you
The National Health Security Office (NHSO) FY2026-2027 National List of Essential Medicines plan prioritises four to eight companion diagnostics panels for inclusion inside oncology bundles under Universal Coverage. Anchor panels are HER2 (breast, gastric), EGFR (lung), BRCA (breast, ovarian), KRAS (colorectal), ALK (lung), and PD-L1 (multiple indications). Reimbursement rates land in the THB 8,000-15,000 range per CDx test depending on panel breadth, materially below private-pay Thai ASPs of THB 18,000-32,000. NHSO bundle inclusion is the single largest demand catalyst behind the THB 12-19B 2027 market projection; independent reference labs and pharma-paired CDx programmes are positioned to capture the scaling NHSO volume.
What not to do with it
Use the linked report for interpretation and keep basis differences explicit.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand Precision Medicine Market Size — 2027 Projection
NHSO NLEM planning documents, Thai FDA NGS CDx framework draft, lab operator filings, hospital programme disclosures, Insight Research triangulation
Genome Thailand Cohort Size — 2026 Milestone
DMSc Genome Thailand programme documents, NIH-DMSc, MoPH
Thailand Hospital-Integrated Personalised Cancer Package ASP
BDMS, Bumrungrad, BNH, Vejthani programme disclosures, Insight Research triangulation
Thailand Precision Medicine Test-Type Mix — 2026 Estimate
Lab operator filings, hospital programme disclosures, NHSO planning documents, Insight Research triangulation
Thailand Precision Medicine Operator Concentration — Top 6 Share
Operator disclosures, hospital programme websites, lab filings, Insight Research triangulation
Thailand Clinical NGS Oncology Panel Cost-of-Goods (50-gene panel)
Lab operator filings, Asia Genomics, Quantum Tech), reagent supplier benchmarks, Insight Research triangulation
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.